Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Turning Point Therapeutics Inc (TPTX) USD0.0001

Sell:$104.08 Buy:$104.42 Change: $1.27 (1.23%)
Market closed |  Prices as at close on 23 November 2020 | Switch to live prices |
Change: $1.27 (1.23%)
Market closed |  Prices as at close on 23 November 2020 | Switch to live prices |
Change: $1.27 (1.23%)
Market closed |  Prices as at close on 23 November 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies. Its tyrosine kinase inhibitors (TKIs) pipeline targets numerous genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The Company has developed a macrocycle platform enabling to design proprietary small, compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors. The Company’s lead drug candidate, repotrectinib (TPX-0005), is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.

Contact details

10628 Science Center Dr Ste 200
San Diego
United States
+1 (858) 9265251

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$4.97 billion
Shares in issue:
48.17 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Sheila Gujrathi
    Chairman of the Board
  • Athena Countouriotis
    President, Chief Executive Officer, Director
  • Yi Larson
    Chief Financial Officer, Executive Vice President
  • Siegfried Reich
    Executive Vice President, Chief Scientific Officer
  • Annette North
    Executive Vice President, General Counsel, Secretary
  • Mohammad Hirmand
    Executive Vice President, Chief Medical Officer
  • Brian Baker
    Vice President - Finance and Administration
  • Heather Adams
    Vice President of Human Resources

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.